William Blair Has Bearish Estimate for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Investment analysts at William Blair decreased their Q2 2025 EPS estimates for Charles River Laboratories International in a research note issued to investors on Wednesday, February 19th. William Blair analyst M. Smock now forecasts that the medical research company will earn $2.40 per share for the quarter, down from their prior estimate of $2.58. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.36 EPS, Q1 2026 earnings at $2.43 EPS, Q2 2026 earnings at $2.60 EPS and Q3 2026 earnings at $2.63 EPS.

A number of other research firms have also weighed in on CRL. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday. Barclays cut their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $195.71.

Charles River Laboratories International Trading Up 0.5 %

Shares of NYSE:CRL opened at $163.11 on Friday. The stock has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International has a 1 year low of $150.79 and a 1 year high of $275.00. The firm has a fifty day moving average price of $172.84 and a 200 day moving average price of $188.09. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 earnings per share.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRL. Creative Planning raised its position in Charles River Laboratories International by 4.0% in the third quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after purchasing an additional 180 shares in the last quarter. Blue Trust Inc. grew its stake in Charles River Laboratories International by 28.6% during the third quarter. Blue Trust Inc. now owns 1,877 shares of the medical research company’s stock worth $388,000 after buying an additional 418 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Charles River Laboratories International during the third quarter worth about $83,800,000. Riverwater Partners LLC grew its stake in Charles River Laboratories International by 2.3% during the third quarter. Riverwater Partners LLC now owns 5,643 shares of the medical research company’s stock worth $1,089,000 after buying an additional 126 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Charles River Laboratories International by 152.6% during the third quarter. Assenagon Asset Management S.A. now owns 49,030 shares of the medical research company’s stock worth $9,657,000 after buying an additional 29,621 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).